Abivax SA (ABVX) - Total Assets
Based on the latest financial reports, Abivax SA (ABVX) holds total assets worth €584.34 Million EUR (≈ $683.16 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ABVX cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Abivax SA - Total Assets Trend (2013–2025)
This chart illustrates how Abivax SA's total assets have evolved over time, based on quarterly financial data. See ABVX net asset value for net asset value and shareholders' equity analysis.
Abivax SA - Asset Composition Analysis
Current Asset Composition (December 2025)
Abivax SA's total assets of €584.34 Million consist of 94.3% current assets and 5.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 88.4% |
| Accounts Receivable | €10.49 Million | 1.8% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €6.61 Million | 1.1% |
| Goodwill | €18.42 Million | 3.2% |
Asset Composition Trend (2013–2025)
This chart illustrates how Abivax SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Abivax SA (ABVX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abivax SA's current assets represent 94.3% of total assets in 2025, an increase from 14.6% in 2013.
- Cash Position: Cash and equivalents constituted 88.4% of total assets in 2025, up from 7.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 85.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 3.2% of total assets.
Abivax SA Competitors by Total Assets
Key competitors of Abivax SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Abivax SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.75 | 1.82 | 1.47 |
| Quick Ratio | 8.75 | 1.82 | 1.47 |
| Cash Ratio | 0.00 | 0.93 | 0.00 |
| Working Capital | €488.22 Million | €76.67 Million | €11.60 Million |
Abivax SA - Advanced Valuation Insights
This section examines the relationship between Abivax SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 18.38 |
| Latest Market Cap to Assets Ratio | 14.17 |
| Asset Growth Rate (YoY) | 184.7% |
| Total Assets | €584.34 Million |
| Market Capitalization | $8.28 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Abivax SA's assets at a significant premium (14.17x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Abivax SA's assets grew by 184.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Abivax SA (2013–2025)
The table below shows the annual total assets of Abivax SA from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €584.34 Million ≈ $683.16 Million |
+184.73% |
| 2024-12-31 | €205.23 Million ≈ $239.93 Million |
-37.25% |
| 2023-12-31 | €327.06 Million ≈ $382.37 Million |
+345.88% |
| 2022-12-31 | €73.35 Million ≈ $85.76 Million |
-33.54% |
| 2021-12-31 | €110.36 Million ≈ $129.03 Million |
+54.79% |
| 2020-12-31 | €71.30 Million ≈ $83.35 Million |
+37.83% |
| 2019-12-31 | €51.73 Million ≈ $60.48 Million |
-4.29% |
| 2018-12-31 | €54.05 Million ≈ $63.19 Million |
+0.43% |
| 2017-12-31 | €53.81 Million ≈ $62.92 Million |
-11.19% |
| 2016-12-31 | €60.60 Million ≈ $70.84 Million |
-20.55% |
| 2015-12-31 | €76.27 Million ≈ $89.17 Million |
+100.88% |
| 2014-12-31 | €37.97 Million ≈ $44.39 Million |
-1.29% |
| 2013-12-31 | €38.46 Million ≈ $44.97 Million |
-- |
About Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials f… Read more